Zydus gets emergency use approval from DCGI for use of ‘Virafin’ in treating moderate COVID-19 infection

23 Apr 2021 Evaluate

Zydus Cadila has received Restricted Emergency Use Approval from the Drug Controller General of India (DCGI) for the use of ‘Virafin’, Pegylated Interferon alpha-2b (PegIFN) in treating moderate COVID-19 infection in adults. A single dose subcutaneous regimen of the antiviral Virafin will make the treatment more convenient for the patients. When administered early on during COVID, Virafin will help patients recover faster and avoid much of the complications. Virafin will be available on the prescription of medical specialist for use in hospital/institutional setup.

Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.

Zydus Lifesciences Share Price

883.80 -0.20 (-0.02%)
16-Jan-2026 10:50 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1678.70
Dr. Reddys Lab 1194.95
Cipla 1400.90
Zydus Lifesciences 883.80
Lupin 2206.50
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×